Welcome to our dedicated page for Nutex Health SEC filings (Ticker: NUTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nutex Health Inc. (NUTX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nutex Health is a Houston-based, physician-led healthcare management and operations company with a Hospital Division and a Population Health Management Division, and its filings explain how these segments are reflected in its financial statements and risk disclosures.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Nutex Health presents consolidated financial statements, segment revenue for its hospital and population health management divisions, details on operating costs, noncontrolling interests and non-GAAP metrics such as EBITDA and Adjusted EBITDA. Recent filings also describe restatements of prior financial statements, including reclassification of non-cash stock-based compensation obligations related to under-construction and ramping hospitals, and explain that these adjustments were non-cash and did not materially affect key metrics such as revenue, liquidity, operating cash flow, Adjusted EBITDA or patient visits for the periods presented.
Current reports on Form 8-K document material events such as the release of quarterly and annual earnings, notices from Nasdaq regarding timely filing requirements and subsequent confirmation of regained compliance, appointment of senior executives, authorization of stock repurchase programs and disclosure of litigation, including a derivative action filed in federal court. These 8-K filings help investors understand significant developments between periodic reports.
On Stock Titan, Nutex Health filings are updated in near real time from EDGAR and are accompanied by AI-powered summaries that highlight key points from lengthy documents. Users can quickly see where Nutex Health discusses topics such as arbitration-related revenue through the Independent Dispute Resolution (IDR) process, capital structure, stock-based compensation, and legal or regulatory matters. The filings page also surfaces ownership and transaction data from forms such as Form 4, enabling readers to review insider transactions alongside the company’s broader financial and operational disclosures.
Nutex Health, Inc. appointed Michael L. Reed as Lead Independent Director effective
Nutex Health Inc. reports that a putative securities class action was filed on August 22, 2025 in the U.S. District Court for the Southern District of Texas, captioned Anjana Bhagavan v. Nutex Health Inc. (Case No. 4:25-cv-03999).
The complaint names the company, its Chairman and Chief Executive Officer, its Chief Financial Officer, and its President and Director as defendants and asserts claims under Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5. The allegations track a recent short seller report, and the plaintiff seeks unspecified damages.
Nutex Health disputes the allegations and intends to vigorously defend the lawsuit. The company states it cannot predict the outcome or estimate the financial impact, but acknowledges that an adverse ruling could have a material adverse effect on its financial position or results of operations.
Nutex Health Inc. filed a current report announcing that on August 14, 2025 it issued a press release with certain anticipated financial results and related information. The company furnished this press release as Exhibit 99.1, specifying that the information in Item 2.02 and the exhibit is being provided for informational purposes and is not deemed filed under the Exchange Act, nor automatically incorporated into other securities filings unless specifically referenced.
Nutex Health Inc. filed a notice that it will be late filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025. The company says it needs additional time to analyze the classification of certain equity instruments and to finalize its financial statements, and that filing on time would require unreasonable effort and expense.
Nutex states it expects to file the Form 10-Q within the five-calendar-day extension period allowed under SEC rules. The company confirms that all other required periodic reports over the past 12 months have been filed. It also indicates that the upcoming Form 10-Q will reflect a significant change in results of operations compared with the same period in the prior year.
Nutex Health (NASDAQ:NUTX) filed Definitive Additional Proxy Materials (DEFA14A) on June 27, 2025, supplementing its June 2, 2025 proxy statement.
The filing simply alerts shareholders that an updated proxy supplement is available, reiterates the July 14, 2025 Annual Meeting date (10:00 a.m. CT), and explains how to request or download materials via ProxyVote.com, phone, or email.
No new proposals, financial data, executive changes, or compensation revisions were disclosed.